



(51) International Patent Classification:

A61K 47/64 (2017.01) A61P 21/00 (2006.01)

(21) International Application Number:

PCT/US2018/035660

(22) International Filing Date:

01 June 2018 (01.06.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/562,146 22 September 2017 (22.09.2017) US
PCT/US2017/066509

14 December 2017 (14.12.2017) US

(71) Applicant: SAREPTA THERAPEUTICS, INC.

[US/US]; 215 First Street, Suite 415, Cambridge, Massachusetts 02142 (US).

(72) Inventors: PASSINI, Marco A.; 215 First Street, Suite

415, Cambridge, Massachusetts 02142 (US). HANSON, Gunnar J.; 215 First Street, Suite 415, Cambridge, Massachusetts 02142 (US).

(74) Agent: STEFFE, Eric K. et al.; Sterne, Kessler, Goldstein

& Fox P.L.L.C., 1100 New York Avenue N.W., Washington, District of Columbia 20005-3934 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY

Figure 1



(57) Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.

